Abivax (ABVX) Announces $150M ATM Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
November 19, 2024 4:30 PM ESTAbivax Establishes an At-the-Market (ATM) Program on Nasdaq
PARIS, France, November 19, 2024 10:30PM CET Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq - ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (ATM Program) allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in... More
